Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

they have a significant influence over the performance of the biotech sector as a whole. While investors may not be able to capitalize on the catalysts that "made or broke" these companies in Q1 ...

“While macro headlines/tweets continue to dictate stock performance, and we expect volatility to continue, we see biotech ...

On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s ‘Power Lunch’ to discuss investing in biotech and the oversaturation in the sector. He said that looking at ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large ...

Many experts rank BMRN as one of the most profitable stocks in the biotech industry due to its solid financial performance and potential for future growth. The company is working on its ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

Medicamen Biotech, operating in the Pharmaceuticals sector and classified as a Smallcap ... a low of ₹377 and a high of ₹630. In terms of performance, Medicamen Biotech has shown a return ...

Ajooni Biotech, operating in the Animal/Shrimp Feed sector and classified as a Smallcap ... of ₹4.95 and a high of ₹10.34. In terms of performance, Ajooni Biotech has shown a return of ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...